Novo Nordisk Sues Sanofi-Aventis Over Insulin Delivery Patents

Law360, New York (September 6, 2005, 12:00 AM EDT) -- Danish drug maker Novo Nordisk A/S has sued its French rival Sanofi-Aventis over patents for its device for administering insulin to people living with diabetes.

Sanofi-Aventis’ handheld OptiClik is an insulin delivery device, or “insulin pen” for Type 1 and Type 2 diabetes. Novo Nordisk alleges the device infringes on of its patents, prompting the complaint filed in U.S. District Court for Delaware.

The complaint accuses Sanofi-Aventis of willful and deliberate infringement, while seeking attorney’s fees, as well as preliminary and permanent injunctions. Also named in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.